MedTrace Logo

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

NCT03061305 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 58213

Last updated 2025-01-31

No results posted yet for this study

Summary

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.

The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.

Conditions

Sponsors & Collaborators

  • Strata Oncology

    lead INDUSTRY

Principal Investigators

  • Scott Tomlins, MD · Strata Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2024-06-27
Completion
2024-06-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061305 on ClinicalTrials.gov